Armata Gets $3.7M DoW Funding, Total Hits $32.4M for Phage Therapy
Los Angeles – September 23, 2026 -- Armata Pharmaceuticals has received an additional $3.7 million in non-dilutive funding from the U.S. Department of War, pushing cumulative government support for its lead bacteriophage candidate AP-SA02 to approximately $32.4 million.
New funds mark first Phase 3-specific allocation under existing DoW award
The $3.7 million tranche represents the first capital earmarked specifically for Phase 3 execution under a previously announced award, following $28.7 million already disbursed. The funding flows through the Medical Technology Enterprise Consortium and is managed by the Naval Medical Research Command's Naval Advanced Medical Development unit, with backing from the Defense Health Agency and Joint Warfighter Medical Research Program.